Released Nov 7, 2024, before the open
10-Q filed Nov 7, 2024, 38 days after period end · 0001785530-24-000034
Q3 2024 · 10-Q
Revenue—
Net Income-$16.67M-$16.67M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.38-$0.38 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$17,124,000N/M
Operating Cash Flowderived-$12,462,000N/M
Free Cash Flowderived-$12,465,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$16.67M | -$8.29M | -$11.94M | -$13.76M |
| EPS Diluted | -$0.38 | -$0.23 | -$0.40 | -$0.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR